Icatibant

A detailed overview of Icatibant, a medication used in the treatment of hereditary angioedema.

Icatibant

Chemical structure of Icatibant

Icatibant is a medication used primarily in the treatment of hereditary angioedema (HAE), a rare genetic condition characterized by recurrent episodes of severe swelling. It is a synthetic peptide and functions as a selective bradykinin B2 receptor antagonist.

Mechanism of Action

Icatibant works by blocking the bradykinin B2 receptor, which is involved in the inflammatory process that leads to the symptoms of hereditary angioedema. By inhibiting this receptor, icatibant reduces the effects of bradykinin, a peptide that causes blood vessels to dilate and become more permeable, leading to swelling.

Clinical Use

Icatibant is administered via subcutaneous injection and is used to treat acute attacks of hereditary angioedema. It is particularly effective in reducing the duration and severity of swelling episodes. Patients are often trained to self-administer the medication at the onset of an attack.

Side Effects

Common side effects of icatibant include injection site reactions, such as redness, swelling, and pain. Other potential side effects may include fever, dizziness, and headache. It is generally well-tolerated, but patients should be monitored for any adverse reactions.

Pharmacokinetics

Icatibant is rapidly absorbed following subcutaneous administration, with peak plasma concentrations typically reached within 30 to 60 minutes. It has a half-life of approximately 1 to 2 hours, and its effects can last for several hours, providing relief from acute symptoms of hereditary angioedema.

Development and Approval

Icatibant was developed as a targeted therapy for hereditary angioedema, addressing the specific pathophysiological mechanism of the disease. It has been approved for use in several countries and is considered a significant advancement in the management of HAE.

Related pages

• Hereditary angioedema
• Bradykinin
• B2 receptor